Acquisition of Aneuploidy Provides Increased Fitness during the Evolution of Antifungal Drug Resistance

Anna M. Selmecki1, Keely Dulmage1, Leah E. Cowen2, James B. Anderson3, Judith Berman1,4

1 Department of Genetics, Cell Biology and Development, University of Minnesota, Minneapolis, Minnesota, United States of America, 2 Department of Molecular Genetics, University of Toronto, Toronto, Canada, 3 Department of Ecology and Evolutionary Biology, University of Toronto, Mississauga, Ontario, Canada, 4 Department of Microbiology, University of Minnesota, Minneapolis, Minnesota, United States of America

Abstract

The evolution of drug resistance is an important process that affects clinical outcomes. Resistance to fluconazole, the most widely used antifungal, is often associated with acquired aneuploidy. Here we provide a longitudinal study of the prevalence and dynamics of gross chromosomal rearrangements, including aneuploidy, in the presence and absence of fluconazole during a well-controlled in vitro evolution experiment using Candida albicans, the most prevalent human fungal pathogen. While no aneuploidy was detected in any of the no-drug control populations, in all fluconazole-treated populations analyzed an isochromosome 5L [i(5L)] appeared soon after drug exposure. This isochromosome was associated with increased fitness in the presence of drug and, over time, became fixed in independent populations. In two separate cases, larger supernumerary chromosomes composed of i(5L) attached to an intact chromosome or chromosome fragment formed during exposure to the drug. Other aneuploidies, particularly trisomies of the smaller chromosomes (Chr3–7), appeared throughout the evolution experiment, and the accumulation of multiple aneuploid chromosomes per cell coincided with the highest resistance to fluconazole. Unlike the case in many other organisms, some isolates carrying i(5L) exhibited improved fitness in the presence, as well as in the absence, of fluconazole. The early appearance of aneuploidy is consistent with a model in which C. albicans becomes more permissive of chromosome rearrangements and segregation defects in the presence of fluconazole.

Introduction

Candida albicans is the most prevalent fungal pathogen of humans and is commonly treated with fluconazole because of its low toxicity, low cost and oral availability. The acquisition of drug resistance is an evolutionary process that occurs because antimicrobials rarely kill an entire population [1]. The survivors are subject to strong natural selection for resistant phenotypes in the presence of a drug. The increasing use of prolonged courses of fungicidal antifungal therapies increases the incidence of acquired antifungal drug resistance [reviewed in [2–4]]. Fluconazole is especially prone to result in resistance as it is fungistatic, not fungicidal and the effective size of surviving populations is large. Furthermore, resistant subpopulations appear to be maintained in the host, since previously treated patients have a higher incidence of resistance to subsequent fluconazole treatments [5].

The evolution of drug resistance depends on phenotypic variability, and the ultimate source of that variability has been considered to be mutations that alter gene expression or protein activities [e.g., [6]]. Recent studies indicate that copy number variation (CNV), including short segmental CNV and whole chromosome aneuploidy, are important contributors to genetic variability in human diseases, as well as to the acquisition of resistance to chemotherapeutic agents by tumor cells [7,8]. Indeed, in S. cerevisiae, the increased frequency of CNV and aneuploidy over point mutations during experimental evolution is an indication of the fitness benefit these mutations convey [9]. Fungi exposed to antifungal agents also exhibit high levels of aneuploidy [10–13].

In addition to genetic changes in DNA sequence and/or copy number, reproductive output, used to estimate fitness, is an important component of a resistance phenotype [14]. The ability of a pathogen with an altered genotype to survive in the presence and in the absence of drug greatly influences the degree to which that genotype will proliferate in the population and the degree to which it can be targeted if drug regimens are changed. However, the fitness effect of CNVs in the presence and absence of drugs has not been studied systematically. In particular, the dynamics of aneuploidy acquisition, fixation and change in a population over the course of physiologically relevant drug treatment have not been examined.

Molecular mechanisms of resistance to fluconazole are well documented and include alterations of two general processes. First, lanosterol 14-alpha-demethylase, which catalyzes a critical step in
Author Summary

C. albicans, the most prevalent human fungal pathogen, acquires resistance to fluconazole by genetic alterations that often include changes in the number of chromosomes or chromosome arms (aneuploidy). Here we demonstrate that chromosomal rearrangements resulting in increased gene dosage are the predominant means of acquired resistance to the antifungal drug fluconazole in replicated experimental populations of C. albicans. A specific aneuploidy, isochromosome 5L, which is composed of two copies of the left arm of Chr5, occurs with high frequency and is detectable soon after fluconazole exposure. The early appearance of aneuploidy in some populations is consistent with a model in which C. albicans becomes more permissive of chromosome rearrangements and segregation defects in the presence of fluconazole. The results presented here indicate that the C. albicans genome is highly plastic and imply that exposure to an antifungal drug induces genome reorganization events, some of which provide a fitness advantage in the presence of drug.

The evolution of drug resistance has been studied by following the azole drugs and alterations in this enzyme structure or increases in the level of the protein confer resistance [reviewed in 4]. Second, drug efflux via ABC transporters (encoded by CDR1 and CDR2) or via the major facilitator superfamily efflux pump (encoded by MDR1) decreases effective intracellular drug levels, allowing cells to survive in the presence of higher extracellular drug concentrations. Increased activity of these processes can be achieved through point mutations in genes encoding the proteins [15] or in transcription factors that regulate them [16–18]. Expression levels [19] or physical copy numbers of these genes can also be increased via genome rearrangements such as whole chromosome and segmental aneuploidies [11,20].

Alteration in gene copy number is a major mechanism for environmental adaptation of sexual yeast populations [21,22]. In C. albicans, karyotype variability appears in many clinical isolates [23] as well as in some laboratory strains [24,25]. Aneuploidy is especially common in fluconazole resistant (FluR) strains: approximately 50% of FluR strains carried a whole chromosome or segmental aneuploidy, while only 10% of fluconazole sensitive (FluS) strains exhibit any type of aneuploidy [11]. One specific segmental aneuploidy, i(5L) (an isochromosome composed of two identical chromosome arms [Chr5L flanking a centromere], increases gene copy numbers of Chr5L at least 2 fold relative to Chr5R, and appears in >20% of drug resistant strains [12/57 strains analyzed] [11], and A.S. and J.B., unpublished data). The appearance of i(5L) is highly correlated with the appearance of increased FluR, and this FluR is primarily due to the presence of two genes on Chr5L that contribute additively and independently to FluR [20]: ERG11 is located ~150 kb from the left telomere and TAC1, a transcription factor that activates CDR1 and CDR2 expression [17,26], is located ~48 kb from the centromere. Despite the high prevalence of CNVs in FluR isolates, no systematic characterization of CNV dynamics has been performed on isogenic C. albicans strains throughout the course of fluconazole treatment.

The evolution of drug resistance has been studied by following patient isolates over time. These studies are useful because they provide information about the evolutionary pressures occurring in the patient. For example, data from isolates taken from a patient that acquired FluR have revealed the homozygosis of point mutations in ERG11 [27] and in TAC1 [26]. We recently found that i(5L) was acquired twice, in two genetically distinct bloodstream isolates from an individual patient, and that its appearance correlated with increases in the fluconazole minimal inhibitory concentration (MIC) [29], indicating that active changes in chromosome copy number are an important mechanism for the evolution of antifungal resistance in the clinical setting. However, studies of chronological patient samples are limited because the consecutive events that led to establishment of a specific strain are only inferred [28].

Experimental evolution permits more direct observation of the dynamics of genetic and genomic changes in identical starting populations exposed to a known selective pressure. Multiple, parallel experiments can be performed with controlled conditions of population size and selection pressure in an environment which facilitates sampling of the population throughout the evolutionary process. In addition, they permit analysis of the fitness consequences of those genetic changes and of the frequency of a given genomic change in the population. Parallel evolution of similar genetic changes under identical selection conditions provides strong evidence that these mutations provide an adaptive advantage [29]. For example, evolution of E. coli for 20,000 generations resulted in strains with similar expression profiles [30].

Experimental evolution of haploid and/or diploid S. cerevisiae in limiting nutrient conditions led to amplification of chromosome regions between highly similar genetic loci [21,31,32], as well as reproducible segmental aneuploidies that were specific to the selection environment [29]. In addition, one diploid strain gave rise to trisomy of three whole chromosomes [29].

In the presence of drug, cells that acquire drug resistance are generally more fit than the ancestral strain. In the absence of drug, the relative fitness of these two strains varies [6,33]. In a previous study, Cowen et al. (2000) performed experimental evolution of a single drug sensitive C. albicans strain, T118, a strain isolated from an oral swab from a patient that was HIV positive. They used a single colony to seed a liquid culture for one round of overnight growth and then divided this culture into 12 independent T118-derived populations: 6 in the absence of drug (N1–N6) and 6 in the presence of drug (fluconazole, D7–D12). Serial cultures were propagated for ~330 generations of growth. Each time a culture grew, the amount of fluconazole added to each population was double the MIC. Three independent drug-treated populations acquired very high levels of FluR and we previously found that i(5L) was present in these three populations (D9-330, D11-330, and D12-165) [11].

Here we studied the evolutionary dynamics of aneuploidy in these twelve batch culture lineages by performing genetic sampling throughout the entire experiment as well as of individuals within mixed subpopulations at times when gross chromosomal rearrangements arose. We performed contour-clamped homogeneous electric field (CHEF) karyotype analysis followed by Southern hybridization to detect gross chromosomal rearrangements, along with comparative genome hybridization (CGH) analysis to detect alterations in chromosome copy number. In addition, we determined the frequency of genome changes by analyzing multiple clones from many of the populations. Following the evolution of initially isogenic populations enabled us to address several questions about the evolution of aneuploidy in C. albicans: how early did aneuploidy arise in these populations? What were the dynamics of aneuploid chromosome acquisition and loss in the presence and absence of drug selection? Did specific aneuploidy arise with similar dynamics in different populations? Furthermore, we performed experiments to ask about the fitness effects of the aneuploidies in the presence and absence of fluconazole. We found
no evidence for aneuploidy or karyotype changes in the untreated populations or parental strain at any time point. Nonetheless, we found that two specific aneuploid chromosomes, i(5L) and trisomy of Chr7, were detectable within the first drug-exposed passage of all three populations that became highly FluR. Furthermore, additional aneuploidies appeared and disappeared over the course of the experimental evolution. Interestingly, in most cases these aneuploid cells, which carried almost 20% more total DNA content than the progenitor cells, had a clear growth advantage in the presence of fluconazole. Thus, exposure to an antifungal drug led to positive selection of specific aneuploidies and gross chromosomal rearrangements.

Results
Karyotype changes are present in early populations that ultimately evolve high levels of FluR
To follow genome dynamics during the evolution of FluR under controlled experimental conditions, we analyzed three independent fluconazole treated populations (D9, D11 and D12) that developed very high levels of FluR (MIC peaks of ~96 µg/ml) ([6] and Figure 1A). We also analyzed six non-drug treated populations derived from the same progenitor strain. In a previous study, we detected i(5L) and other aneuploidies in samples with the highest MIC values from populations that had undergone an estimated

**Figure 1. Drug resistance profiles throughout evolution.** (A) Populations evolved with fluconazole (D9, D11, and D12) adapted to the drug and showed increased fluconazole MIC [6]. Populations evolved without fluconazole (N1–N6) show no change in MIC and (B) maintain karyotype stability. Whole chromosomes were separated by CHEF, stained with Ethidium Bromide (Left) and (C) subjected to Southern hybridization with a CEN5 probe. Lane P, the progenitor strain karyotype.
doi:10.1371/journal.pgen.1000705.g001
330 or 165 doublings (D9-330, D11-330 and D12-165) [11]. The i(5L) in the tested D9 and D11 samples co-migrated with Chr7 (≈950 kb), the size expected (≈945 kb) for independent i(5L) composed of two copies of Chr5L plus CEN5. In the D12-165 sample, the extra Chr3L sequences were found in a much larger band that co-migrated with Chr2 (≈2.2 Mb). Southern analysis demonstrated that this large band was composed of an intact i(5L) attached through a telomere-telomere fusion to the left telomere of an intact copy of Chr3 to form an attached isochromosome 5L (att-i(5L)) [11]. While i(5L) was detected in all three populations, the dynamics of the appearance of i(5L) and other aneuploidies was not known. We did not know when it had arisen and whether or not it had become fixed in the population. Furthermore, while strains containing i(5L) often carried other aneuploid chromosomes as well, it was not clear if those other aneuploidies were more or less stable than the i(5L) in the populations.

To address questions concerning the dynamics of genome change in these populations, we analyzed the untreated populations (N1 through N6) and all of the time points from the three drug treated populations (D9, D11, and D12) on CHEF karyotype gels stained with EtBr (Figure 1B and Figure 2A-2C), and then analyzed them by Southern hybridization with a CEN5 probe (Figure 1C and Figure 2D-2F), which detects the i(5L) that co-migrates with Chr7 [11]. In D9, the EtBr-stained karyotypes of early cultures appeared generally unchanged, other than a minor change in Chr5 Major Repeat Sequence (MRS) length (A.S. and J.B., unpublished data) and the appearance of a new band below Chr4 in three later populations (Figure 2D, arrow, discussed below). Surprisingly, Southern analysis revealed a band corresponding to the size of i(5L) in all the evolved cultures, including the ~3.3 generation isolate. However, the intensity of hybridization in D9-3.3 was lower than in the other populations (Figure 2D). Similar results were seen in population D11, except that hybridization of the CEN5 probe to i(5L) was stronger than in D9-3.3 (Figure 2E). In the D12 CHEF karyotypes, the acquisition of the att-i(5L) also was evident within the earliest ~3.3 generation isolate (Figure 2E and 2F) and the shorter Chr5 homolog (MTLa, data not shown) ‘disappeared’ at the same time. Importantly, this att-i(5L) was composed of 3 copies of the MTLa copy of Chr5L [11]. In contrast, the i(5L) in D9-3.3 and D11-3.3 were composed of 2 copies of the MTLa copy of Chr5, indicating that the i(5L) in D12 arose independently from the i(5L) found in D9 and D11 populations. At later generations 260, 300 and 330, the att-i(5L) ‘disappeared’ and the MTLa homolog of Chr5 ‘reappeared’. This is consistent with the idea that two events occurred: an i(5L) formed from the MTLa homolog of Chr5L and it also became attached to the shorter homolog of Chr5 to form the att-i(5L). Later in the evolution of the culture, the i(5L) portion of the att-i(5L) was lost. Thus, in all three cultures that evolved high levels of FluR, either i(5L) or att-i(5L) was detectable at the earliest sampling of the cultures.

Importantly, neither i(5L) nor any other gross chromosomal rearrangement was detected in the progenitor T118 or in populations that were not treated with drug (Figure 1B and 1C and data not shown). Furthermore, i(5L) was not detected in early time points from drug-treated populations that did not develop high levels of FluR (D7, D8 and D10, data not shown). In addition, populations of T118 progenitor cells plated on fluconazole concentrations do not contain drug resistant colonies (data not shown). Taken together with the appearance of two different forms of i(5L) generated from different MTLa alleles, this suggests that the different forms of i(5L) either arose late during growth of the original progenitor colony used to seed all 12 cultures or that the two different isochromosomes arose within the first 24 hours of drug exposure. In either case, growth in fluconazole was selective for the i(5L).

While only semi-quantitative, Southern analysis of CHEF gels suggested that i(5L) may not be present in all cells in some of the populations such as D9-3.3. To address this issue more directly, we analyzed individual colonies from a number of the time points, to ask if the i(5L) was present in each of the progenitor cells that gave rise to the colonies. Again, CHEF karyotype gels were first analyzed with EtBr and were then subjected to Southern analysis using the CEN5 probe. An example of the results for colonies derived from the D9-3.3 population is shown (Figure 3). Similar analyses were performed for clones from other populations (Figures S1, S2, S3) and the results are summarized in Table 1.

As expected for a mixed population of adaptive mutants, 3 of 16 (19%) of the D9-3.3 clones (individual colonies) contained the i(5L). By the next time point tested (D9-140) all clones carried the i(5L), indicating that it had become fixed in the population. Of note, there was heterogeneity in the genome structures of different clones. For example, the MTLa homolog of Chr5 was lost in clone D9-3.3 E (Figure 3A and 3B and data not shown).

Despite the higher proportion of i(5L) at the D11-3.3 time point, i(5L) did not become fixed as rapidly in this population. After 3.3 doublings, 94% (15 out of 16 clones) contained i(5L); after 50 doublings i(5L) was detected in 73% of the population and by 140 doublings the number decreased to 50% of the clones tested. From 200 doublings on, all clones included an i(5L), suggesting that it had swept the population after 200 doublings.

In D12-3.3 and D12-50, the att-i(5L) was present in all clones analyzed, suggesting that it appeared early after drug exposure. Although CHEF analysis detected a small amount of independent i(5L) (not attached) in population D12-50 (Figure 2F), it was not detectable in any of the 10 clones analyzed. Interestingly, the loss of att-i(5L) appears to have been abrupt as well: it was present in all of the D12-230 clones (15/15 colonies), but only in 20% of the D12-260 clones (3/15 colonies).

Frequency of i(5L) correlates with fitness levels

The early appearance of i(5L) in all three populations was surprising and could be due to several possible mechanisms. First, it is possible that a subpopulation of the progenitor cells contained i(5L) and that their increased fitness in the presence of drug caused them to be rapidly selected [34]. We consider this unlikely because no i(5L) was detected in early cultures from strains D7, D8 and D10 under drug selection. In the D8 population, i(5L) never appeared and in D7 and D10, which acquired transient peaks of FluR (MIC ~4 to 8), i(5L) appeared only in the peak populations (A.M.S., data not shown). Furthermore, since two types of i(5L) (attached MTLa/a/a and independent MTLa/a) appeared in independent populations, both types would have had to be present in a few cells in the progenitor population and thus each population would have been heterogeneous for different types of i(5L).

Second, it is possible that each i(5L) formed during the 24-hour period of fluconazole stress. Once formed, i(5L) could sweep through the populations if it provided very strong selective advantage in the presence of drug, such that clones that had acquired it out-competed clones within the population that had not acquired it. To ask if this was the case, we compared the fitness of clones with or without i(5L) by directly competing each clone with the drug sensitive ancestor (T118), in the presence and absence of fluconazole, by measuring the reproductive output of each competitor in the final mixture (Figure 3C). In the presence of fluconazole, all clones at generation ~3.3 that contained an i(5L) exhibited significantly increased fitness relative to the clones.
Figure 2. Rapid acquisition of i(5L) occurred in all fluconazole treated populations. (A–C) Whole chromosome CHEF gel analysis of populations D9, D11, and D12 at generations 3.3, 50, 140, 260, 300, and 330. (D–F) Southern blot analysis of the CHEF gels using a CEN5 probe identified both Chr5 homologs as well as either independent i(5L) or att-i(5L) at generation 3.3 in all three populations. The i(5L) aneuploidy was detected in all subsequent generations of D9 and D11, while the att-i(5L) was lost in D12 after generation D12-260. The CEN5 probe also hybridized to a novel band at ~1.5 Mb in population D9 (black arrow).

doi:10.1371/journal.pgen.1000705.g002
that had not acquired i(5L): D9-3.3-D, D11-3.3-A and D12-3.3-A, were 24%, 46% and 54% more fit than the progenitor, respectively. In contrast, the non-i(5L) clones (D9-3.3-A and D11-3.3-D) and the non-drug treated strain (N1-3.3) exhibited fitness levels that were not significantly different from the progenitor in the presence of drug. This indicates that i(5L) confers a strong selective advantage in the presence of the drug. Furthermore, the growth rate and maximum cell density achieved by strains containing i(5L) was much higher than that of sibling strains lacking i(5L) (data not shown). Modeling of cell numbers indicates that if i(5L) arose within the first 2 hours of fluconazole exposure, it could have reached 0.2% of the population within the first growth cycle. Thus, selective advantage alone during 24 hours in fluconazole cannot explain how i(5L) reached levels of 15–100% of the population of $10^6$ cells. Importantly, cells were stored in the selective growth medium (plus glycerol) immediately following the experiment. We cannot rule out the possibility that resuscitation of those strains may have involved some additional selection that allowed cells containing i(5L) to reach higher proportions of the population.

A third mechanism by which i(5L) may have become a larger proportion of the population is during subsequent non-selective propagation of the strains. Such propagation was necessary for transfer of the strains between labs and for growth and analysis of

| Population | Number of Single colonies with i(5L) | Total Number of colonies analyzed | Percent of Population with i(5L) |
|------------|-------------------------------------|----------------------------------|-----------------------------|
| D9-3.3     | 3                                   | 16                               | 19%                         |
| D9-140     | 6                                   | 6                                | 100%                        |
| D9-200     | 6                                   | 6                                | 100%                        |
| D9-260     | 9                                   | 9                                | 100%                        |
| D11-3.3    | 15                                  | 16                               | 94%                         |
| D11-50     | 11                                  | 15                               | 73%                         |
| D11-140    | 3                                   | 6                                | 50%                         |
| D11-200    | 6                                   | 6                                | 100%                        |
| D11-260    | 6                                   | 6                                | 100%                        |
| D11-330    | 6                                   | 6                                | 100%                        |
| D12-3.3    | 15                                  | 15                               | 100%                        |
| D12-50     | 10                                  | 10                               | 100%                        |
| D12-230    | 15                                  | 15                               | 100%                        |
| D12-260    | 3                                   | 15                               | 20%                         |

Table 1. Percent of cells in a population with i(5L).
single colonies for CHEF analysis. We estimate that cells underwent ~50–70 divisions in the absence of drug prior to CHEF analysis. In fitness assays conducted under the conditions used for the evolution experiment (RPMI medium with or without drug), the D9-3.3, D11-3.3, and D12-3.3 clones that contained the i(5L) had no significant reduction in fitness relative to the progenitor in the absence of drug (Figure 3E); furthermore, D12-3.3 had a significant increase in fitness relative to the progenitor in the absence of fluconazole and D11 consistently exhibited a slight increase in fitness under these conditions. Thus the D12-3.3 population could have easily accumulated more cells carrying i(5L) during the nonselective growth necessary for CHEF gel analysis. This may be the case for D11-3.3 as well. Interestingly, the proportion of cells containing i(5L) in the ‘3.3’ populations reflects the relative fitness advantage of those strains under non-selective conditions. Thus, we conclude that i(5L) arose early in all three populations and reached appreciable proportions of the population during growth in the first cycle of exposure to fluconazole, but that the very high levels of i(5L) found in the populations analyzed is due to that selection plus some additional selective advantage under no drug conditions.

Multiple aneuploidies are evident in drug-evolved populations

Comparative Genome Hybridization (CGH) performed on a microarray platform that includes probes covering most ORFs in the genome provides a comprehensive view of copy number changes. We used CGH to analyze D9, D11 and D12 populations as well as a number of single colony clones that previously had been analyzed by CHEF karyotype gels and Southern hybridization (e.g., Figure 3, Table 1). In general, strains carrying the ~945 kb i(5L) on CHEF gels also carried two extra copies of Chr5L, but there were exceptions. In D11-200, -260 and -330, there were >5 copies of Chr5L, suggesting that they contained two copies of i(5L) (4 copies of Chr5L) in addition to the normal two copies on intact Chr5 homologs (Figure S7).

CGH of D9 strains was consistent with the CHEF karyotype gel analysis: no i(5L) or other aneuploidies were detected in clone D9-3.3-A, while i(5L) was detected in clone D9-3.3-D (Figure 3A and B). In addition, CGH revealed that Chr3, Chr4 and Chr7 were trisomic in clone D9-3.3-D. Thus, clone D9-3.3-D included multiple aneuploidies that were not evident on the CHEF karyotype gels and its MIC (~3.0 μg/ml), was higher than that of clone D9-3.3-A (~1.5 μg/ml), which had no obvious aneuploidies. This is consistent with the idea that aneuploidies in D9-3.3-D (including, but not limited to i(5L)) confer increased drug resistance. Importantly, the additional whole chromosome trisomies did not impair fitness under either the selective or non-selective growth conditions (Figure 3C) and were observed at generation 330 (discussed below).

Clones from population D11-3.3 (Figure 4C and 4D) were generally similar to the clones from population D9-3.3. D11-3.3-A was trisomic for Chr3 and Chr7 (but not for Chr4) and carried i(5L). Furthermore, as in D9-3.3 clones, the MIC of strains with multiple aneuploidies was slightly higher (~2.0 μg/ml) than the MIC of strains lacking them (~0.5 μg/ml). For D12-3.3, all single

Figure 4. Rapid acquisition of i(5L) coincided with multiple whole chromosome aneuploidies. CGH analysis of single colonies from populations D9-3.3 and D11-3.3 found that clones were either completely diploid (A,D) and had lower fluconazole MICs, or were aneuploid and had higher MICs (B,C). Clone D9-3.3-D (B) contains i(5L) and is trisomic for Chrs 3, 4, and 7, while clone D11-3.3-A (C) contains multiple copies of i(5L) and is trisomic for Chrs 3 and 7.

doi:10.1371/journal.pgen.1000705.g004
colony clones contained i(5L), and thus we could not compare their growth to sister clones lacking i(5L). Importantly, the degree to which D9-3.3, D11-3.3 and D12-3.3 had increased fitness in the presence and absence of drug correlated positively with the proportion of the population that contained aneuploidies (Figure 3C and Table 1).

Aneuploidies detected by CGH in evolved populations and their respective individual clones (Figures S6, S7), are summarized in Table 2 and revealed several interesting findings: First, the proportion of the population that contained aneuploidies correlated positively with the presence and absence of drug, which is consistent with the idea that aneuploidy can promote evolvability under strong selection [22,29,33].

Second, whenever i(5L) was present, Chr7 trisomy was also evident, suggesting that extra copies of Chr7 may enhance the fitness of strains carrying i(5L). However, loss of i(5L), detected only in the D12 series, was not accompanied by coincident loss of Chr7 (described below). Thus, i(5L) and Chr7 do not co-segregate during all changes in chromosome content.

Third, we observed dynamic appearance and subsequent disappearance of different clones/aneuploidies: in D9-3.3 the aneuploid genotype (i(5L) + trisomy of Chr3, 4, & 7) was present in ~15% of the population; in D9-165 trisomy of Chr3 & Chr4 was not evident; in D9-230 and D9-300, a new chromosome band (Figure 2D arrow, discussed below) appeared and then disappeared; and, in D9-330, in addition to i(5L), Chr3R was monosomic, Chr4, 6 and 7 were trisomic and Chr3 had a segmental trisomy. Nonetheless, whole chromosome and segmental aneuploidies detected in single clones at generation 3.3 were highly predictive of the aneuploidies detected in the D9 and D11 populations at generation 330. For example, the aneuploid chromosomes of clone D9-3.3-D (i(5L), Chr3, Chr4, & Chr7) were present in population D9-330, except that the Chr3 trisomy changed to a segmental trisomy. This suggests that, once it becomes aneuploid, the C. albicans genome is dynamic and continues to change. Yet, under fluconazole there was strong selective pressure for a similar repertoire of aneuploidies. Finally, no aneuploidy was detected in the progenitor strain (T118), in the endpoints of each N1 population (N1-330 to N6-330), nor in single colonies from within each endpoint population (N1-330-A to N6-330-A) (Figures S4, S5). Thus, during extended growth in vitro, in the absence of selective pressure, the karyotype did not change.

Table 2. C. albicans strains used (ploidy characterized by CGH).

| Stain Name | Strain Number | Relevant Ploidy |
|------------|---------------|-----------------|
| SC5314     | YJB2348       | Diploid         |
| T118       | YJB9613       | Diploid         |
| T118-Eco1-VAT | YJB10621    | Diploid         |
| N1-330     | YJB10653      | i(5L),Trisomy Chr3, Chr4, Chr7 |
| N2-330     | YJB10654      | i(5L) Trisomy Chr7 |
| N3-330     | YJB10655      | i(5L) Trisomy Chr7 |
| N4-330     | YJB10656      | i(5L) Trisomy Chr7 |
| N5-330     | YJB10657      | i(5L) Trisomy Chr7 |
| N6-330     | YJB10658      | i(5L) Trisomy Chr7 |
| N1-330-A   | YJB10681      | i(5L),Trisomy Chr3, Chr4, Chr7 |
| N2-330-A   | YJB10683      | i(5L), Trisomy Chr7 |
| N3-330-A   | YJB10685      | i(5L), Trisomy Chr7 |
| N4-330-A   | YJB10741      | i(5L), Trisomy Chr7 |
| N5-330-A   | YJB10888      | i(5L), Trisomy Chr7 |
| D8-330     | YJB10734      | i(5L), Trisomy Chr7 |
| D9-3.3-A   | YJB10952      | i(5L), Trisomy Chr7 |
| D9-3.3-D   | YJB10955      | i(5L), Trisomy Chr3, Chr4, Chr7 |
| D9-165     | YJB10873      | i(5L), Trisomy Chr7 |
| D9-260-A   | YJB10970      | i(5L), additional SL, Trisomy Chr6, Chr7 |
| D9-260-B   | YJB10971      | i(5L), additional SL, Trisomy Chr6, Chr7 |
| D9-260-B_CHEF band only | YJB10971-CHEF Band | Trisomy Chr7 |
| D9-260-F  | YJB10975      | i(5L), Trisomy Chr7 |
| D9-330     | YJB8736       | i(5L), Monosomy 5R, Trisomy Chr4, Chr6, Chr7, Segmental Trisomy Chr3 |
| D11-3.3-A | YJB10981      | i(5L), Trisomy Chr3, Chr7 |
| D11-3.3-D | YJB10984      | i(5L), Trisomy Chr3, Chr7 |
| D11-200    | YJB10673      | i(5L), Trisomy Chr7 |
| D11-260    | YJB10675      | i(5L), Trisomy Chr7 |
| D11-330    | YJB8737       | i(5L), Monosomy 5R, Trisomy Chr4, Chr3, Segmental Trisomy Chr3 |
| D12-165    | YJB8738       | i(5L), Trisomy Chr7 |
| D12-165+100 generations without Flu selection | YJB10283 | Trisomy Chr7 |
| D12-260    | YJB8739       | Trisomy Chr4, Chr7 |
| D12-330    | YJB8740       | Trisomy Chr4 |

Transcript appearance of a supernumerary chromosome (SNC) is associated with decreased fitness yet higher MIC relative to the progenitor

A new band with apparent size of ~1.5 Mb appeared in the later D9 populations (D9-230, D9-260 and D9-300, Figure 2D, upper arrow) while i(5L) remained detectable in these populations. Clones from D9-260 grew with two distinct colony size phenotypes (Figure 5A): small colonies that grew slowly (clones D9-260-a to -c) and colonies with a wild-type size and growth rate (clones D9-260-F to -I). CHEF gel analysis indicated that the small colonies contained the ~1.5 Mb SNC as well as i(5L) while the larger colonies retained i(5L) only (Figure 5B). CGH analysis of small and large colonies indicated that both types of colonies contained 2–4 additional copies of Chr3L and were trisomic for Chr7 (Figure 6A and 6B). In addition, small colony D9-260-a was trisomic for Chr6. To ask if the ~1.5 Mb SNC included either Chr3R, Chr6 and/or Chr7 DNA fused to Chr5L DNA, we probed Southern blots of the CHEF with probes from Chr6 (two from 6L and one from 6R), CEN7, the right arm of Chr5, and MT1z on Chr5L (probes are listed in Table S1). None of these probes hybridized to the ~1.5 Mb SNC (Figure 5B and data not shown). This suggests that neither Chr3R, nor Chr6, nor Chr7 are fused to Chr5L in the novel SNC.

We then isolated the ~1.5 Mb SNC from the CHEF gel, labeled it with Cy3 and analyzed the contents of this single chromosome by CGH [21]. As expected, the band included DNA from all of Chr5L including CEN5 and/or orf19.5999.
While this type of analysis cannot directly determine copy number (because one chromosome is hybridized relative to a whole genome), the signal from Chr5L was approximately twice as high as the signal from the Chr3R segment. This is consistent with the size of the fragment and implies that the 1.5 Mb SNC is composed of two copies of Chr5L (most likely organized as an isochromosome, 945 kb) attached to a (600 kb) segment from Chr3R (5L-CEN5-5L::3(orf19.5999→R)tel)). We refer to the 1.5 Mb SNC as i(5L)-3R.

The detection of a Chr3R segment in the isolated 1.5 Mb SNC was surprising since no obvious increase in the number of Chr3R copies was evident in the whole genome CGH of small colony D9-260 clones (Figure 6A and Figure S6B). Southern analysis of whole chromosome CHEF gels confirmed that CDR1, a gene just to the right of DYN1 and within the Chr3R segment, is present on the ~1.5 Mb SNC as well as on intact Chr3. and CDR2, a gene just to the left of DYN1, is not (Figure 5C). A CEN3 probe, located farther to the left of the Chr3R segment breakpoint, is also absent from the ~1.5 Mb SNC (Figure 5C). Consistent with the fusion of Chr3R to an i(5L), the ~1.5 Mb SNC did not include an SfiI restriction site (Figure S8A). Also, since both the independent i(5L) and the i(5L)-3R SNC in these clones carry only the MTLa homolog (Figure S8B), the event that gave rise to the ~1.5 Mb SNC likely involved a non-reciprocal recombination event in which one Chr3R segment was copied onto the end of the i(5L) that was already present in the population.

The stability of the i(5L)-3R SNC was highly variable, with some small colony clones giving rise to all small colonies and some giving rise to small and large colonies. CHEF gel analysis indicates that all of these large colony derivatives had lost the ~1.5 Mb SNC (Figure S8C). In fact, loss of the SNC occurred in isolate D9-260-a during subsequent propagation for CHEF analysis (~20 generations in YPD) (Figure S8A, single colony lane “a”). These observations prompted analysis of fitness and chromosome stability in clones with and without the SNC. The slow growth of clones containing the ~1.5 Mb SNC is consistent with the idea that this SNC caused a burden on cell growth. Indeed, it caused a growth disadvantage in the absence and in the presence of fluconazole relative to the progenitor strain (Figure 6D). The MIC of this subpopulation (48–64 μg/ml) accounts for the MIC of the original D9-260 population (64 μg/ml). Despite the very slow growth of the small D9-260 clones in the presence of drug, the large D9-260 clones grew even less well in fluconazole and had a much lower MIC (8 μg/ml). This implies that the SNC is a beneficial yet costly mutation (Figure 6D). Consistent with the observation that the i(5L)-3R SNC in clone D9-260-a was unstable during culture, a double ellipse of growth formed in the e-strip assay (Figure 6A, insert) one at 64 μg/ml and the other at 8 μg/ml. We propose this is due to loss of the SNC during growth of the colonies on the plate.

Instability of att-i(5L)

In D12, the att-i(5L) was maintained through 230 doublings and then was quickly lost. CGH analysis of these strains detected the i(5L) DNA as well as trisomy of Chr7 (Figure 7A). No other aneuploidies were evident in the strain. Thus, an extra copy of Chr7 accompanied the acquisition of i(5L) in all three of the cultures derived from T118 that reached higher MICs (D9, D11 and D12). A drop in MIC accompanied the loss of the att-i(5L), and the intact MTLα Chr5 homolog, whose mobility was altered upon att-i(5L) formation, was restored (Figure 8A). A similar loss of att-i(5L) and restoration of the original Chr5 homolog was seen in transformants derived from D12-165 (Figure 8B). Importantly, the drop in MIC upon loss of att-i(5L) and retention of Chr7 trisomy...
Figure 7B) suggests that the major contribution to fluconazole resistance came from genes on i(5L), rather than from genes on Chr7. Consistent with this, propagation of D12-165 (att-i(5L) and Chr7 trisomy) in the absence of drug for over 100 doublings (or transformation with NAT1 which sometimes led to i(5L) loss) resulted in a drop in MIC, loss of the att-i(5L) from the population and retention of Chr7 trisomy (Figure 7D).

In the original study, continued evolution of D12-260 for another 70 doublings in the presence of fluconazole (D12-330) was accompanied by loss of Chr7 trisomy, while Chr1 trisomy remained in the culture (Figure 7C). Loss of the i(5L) and Chr7 trisomy resulted in a drop in MIC from 64 μg/ml to 4 μg/ml. This residual FluR, compared to the progenitor, could be due to the extra copy of Chr1 or to other mutations accumulated in the strain during propagation in the presence of the drug.

Discussion

In this study we analyzed changes in genome organization and copy number that are now recognized as important contributors to antifungal drug resistance. In vitro analysis of the evolutionary process in strains with an identical ancestor allowed us to monitor the events that arise and change over time in parallel populations.

Analysis of multiple clones at each generation allowed us to follow specific mutations that occurred at each generation and determine the benefit of those mutations based on their fixation within the population. Importantly, results from this experimental evolution study mirror the analysis of clinical FluR strains: in both cases ~50% of the cultures (3/6 in this study) exhibited aneuploidy associated with the acquisition of FluR and the presence of i(5L) correlated with the highest fluconazole MICs. Furthermore, loss of i(5L) correlated with a drop in fluconazole MIC levels [11,20]. The most surprising result is the early appearance of cells carrying multiple aneuploidies including, but not limited to i(5L). Yet different types of i(5L) were acquired in 3 populations while i(5L) did not appear early in the other three drug-treated populations. Importantly, neither i(5L), nor any other aneuploidy, was detectable in any of the populations that were not exposed to drug. This suggests that under fluconazole stress, either fluconazole is a mutagen or C. albicans cells enter a hypermutable state when exposed to fluconazole [34]. Based on the standard exponential growth model of cell division, cells carrying i(5L) were inadvertently enriched during storage and resuscitation of the original isolates (see Materials and Methods). Nonetheless, the presence of i(5L) in these populations, irrespective of their prevalence, indicates that they...
were present; their fitness advantage indicates that they became increasingly prevalent during propagation in drug.

How does aneuploidy arise so rapidly?

i(5L) was detectable by CHEF in all three populations after one 24-hour passage in fluconazole. During this time the population had undergone an average of 3.3 doublings in the presence of fluconazole. Based on the exponential growth rate model (Materials and Methods) we assume that i(5L) arose early after exposure to fluconazole although we cannot rule out the possibility that a very small number of i(5L) cells existed in the progenitor culture. If i(5L) appeared early after exposure to fluconazole, it would support the model that stress-induced mutagenesis may operate in C. albicans [34]. Consistent with this, stress response signaling through Hsp90 and/or calcineurin is required for fluconazole tolerance [36–38]. Alternatively, fluconazole may function (directly or indirectly) as a mutagen; it has been reported to be clastogenic in mouse bone marrow cells [39] and causes significantly increased levels of loss of heterozygosity in C. albicans (A. Forche and JB, in preparation).

The frequency with which C. albicans undergoes major chromosome rearrangements in fluconazole is apparently higher than the frequency of such events in S. cerevisiae haploid or diploid cells [40]. One explanation offered for the plasticity of the C. albicans genome is that it is not subject to the constraints imposed by meiotic segregation and thus it can retain detectable genome rearrangements that would be lost in organisms that undergo meiosis. Alternatively, C. albicans may lack some cell cycle checkpoints that prevent aneuploidy in other organisms, or it may have an active mechanism to induce concerted chromosome changes like those seen during the parasexual cycle [41]. Whatever the mechanism, it is becoming increasingly clear that aneuploidies are more prevalent than originally thought. For example, ~8% of the original S. cerevisiae deletion collection contained aneuploidies, most of them segmental [42]. Furthermore, in the presence of strong selective pressure, S. cerevisiae nyp2Δ cells with defects in cytokinesis evolved alternative mechanisms of cell division via the acquisition of aneuploidies for specific sets of chromosomes [22]. Similarly, whole chromosome trisomy and higher copy aneuploidies were detected more frequently in diploid than haploid S. cerevisiae cells evolved under nutritional stresses [29]. Thus, while the frequency of aneuploidy in C. albicans (a diploid) is high, S. cerevisiae diploid cells undergo similar types of events when placed under selection pressure. The lack of detectable aneuploidy in untreated cells (Figures S4, S5) and detection of high rates of aneuploidy in drug treated cells ([11] and this study), as well as in strains isolated from patients [20] or from animals [43] suggests that C. albicans is exposed to constant selective pressure when it is propagated in mammalian hosts. We suggest that this selective pressure may be even stronger when C. albicans is exposed to antifungal drugs within the mammalian host.

Variations on Chr5L geometry and copy number

Chr5L appeared in the evolved strains as an independent chromosome of ~945 kb throughout the experiment in two of the cultures (D9 and D11), as an i(5L) attached to a full length Chr5.
(D12), and as an i(5L) attached to a segment of Chr3R in later D9 populations. Chr5L copy number also varied in these strains, irrespective of geometry. For example, multiple copies of independent i(5L) were present in D11 cells (Figure S7); CGH estimates approximately 6 copies of Chr5L. Similarly, D9-260 clones contain Chr5L sequences on 4 different chromosomes with 3 different geometries: intact Chr5 (2 copies), i(5L), and the i(5L)-3R SNC.

In D12, att-i(5L), which includes centromere-to-centromere and telomere-to-telomere orientations of Chr5L, was acquired early and was maintained for over 200 doublings. This structure is potentially dicentric, however micrococcal nuclease digestion studies suggest that one of the three copies of CEN5 in the strain is not packaged into centromeric heterochromatin (Carrie Ketel, unpublished data) and thus is not functional. We presume this is the CEN5 DNA on the i(5L) portion of att-i(5L) since, once detached (in D12-260), this DNA is not stably maintained (Figure 8).

Other aneuploidies in FluR strains

In addition to Chr5L aneuploidy, increased gene copy numbers of chromosomes 3, 4, 6, and 7 were found. Multiple genes known to be important for FluR are found on these chromosomes: The segmental trisomy of Chr3 in strain D9-330 (Figure S6) and Chr3R segment attached to i(5L) on the i(5L)-3R, includes CDR1, which encode the major ABC-transporter important for FluR [45,46], as well as MRR1, which encodes a transcription factor that upregulates MDR efflux pumps [18]. MDR1 is found on Chr6. Increased gene copy number of Chr3 and/or Chr6 is likely the reason that MDR1 is expressed at increased levels in this strain [28].

Additional copies of ERG11 and TAC1 that contribute independently and additively to FluR [20] also contribute to the increased FluR in these strains.

Figure 8. Transformation of att-i5L results in loss of i(5L) and retention of the intact Chr5 portion. (A) Strain D12-165 contains an att-i(5L) chromosome with two CEN5 structures (top) and one normal Chr5 homolog (bottom). Transformation was used to disrupt orf19.1963 on Chr5L with the NAT1 marker. There are 4 existing orf19.1963, three on the att-i(5L) (I, II, III) and one on the full-length Chr5 homolog (IV). (B) CHEF/Southern blot analysis of 13 NAT1 positive transformants indicates that in all but 3 cases the NAT1 insertion occurred on the att-i(5L) at any locus I-III. In the remaining 3 transformants, NAT1 insertion occurred at locus III and coincided with detachment of the i(5L) and reformation of the independent Chr5 homolog. This same phenomenon was observed during the original D12 evolution experiment.

doi:10.1371/journal.pgen.1000705.g008
in D11-300 (>5 gene copies). We propose that extra copies of Chr4 may provide increased levels of FluR because of the increased levels of NCPI. Additional genes on Chr4 that might affect FluR included ERG8, ERG227 and ERG6251, which are all involved in ergosterol biosynthesis. ERG251 is upregulated in response to at least oneazole drug, ketoconazole [47], but it is not known if increased numbers of these genes contribute to drug resistance. Thus, several of the aneuploid chromosomes that became prevalent in the drug treated populations carry genes that have already been shown to be important for increased resistance to fluconazole.

Aneuploidy in C. albicans, as in cancer cells, does not have a high fitness cost

Malignant cancer cells exhibit unrestricted growth and high levels of aneuploidy and polyploidy. Yet most aneuploid S. cerevisiae strains exhibit growth defects under non-selective conditions [48]. This raises an important conundrum: How is it that aneuploidy in cancer cells does not restrain growth, yet aneuploidy in model organisms does? In stark contrast, aneuploidy in C. albicans, like aneuploidy in cancer cells, does not appear to have a high fitness cost. All aneuploides reported here all were detectable after passage for ≥70 generations in non-selective medium (YPD). Other FluR strains also have been propagated extensively under non-selective conditions without loss of i5L. C. albicans aneuploidies are usually increased copies of whole chromosomes whereas S. cerevisiae aneuploidies that arise in haploid cells under selection are primarily shorter segmental aneuploidies [21,29,32]. As an obligate diploid, C. albicans may be better able than haploids to tolerate the acquisition of an extra chromosome (50% vs 100% increase in copy number, respectively). Accordingly, S. cerevisiae diploidies exhibit higher rates of aneuploidy under strong selection [29]. An argument against this simple model is that mice carrying specific trisomies exhibit reduced fitness [49], however we cannot rule out the possibility that some aneuploidies or combinations of aneuploid chromosomes provide a selective advantage under stress conditions that were not tested in these experiments [50]. The concerted appearance of i5L and Chr7 trisomy are consistent with such an idea. We suggest that the acquisition of aneuploidy may be a general mechanism for the rapid evolution of genome change in response to severe stress conditions in C. albicans. At least in C. albicans, aneuploidy appears to arise frequently and is well tolerated, especially in cells responding to physiologically relevant concentrations of fluconazole. Thus, C. albicans and its response to fluconazole, may be an excellent model system for studying the molecular mechanisms that mediate genome changes that occur in mammalian cells in response to carcinogens.

Materials and Methods

Strain propagation and single-colony analysis

All populations were stored during the initial evolution experiment by freezing in growth medium plus 15% glycerol. These populations were revived by streaking to YPD, transferred between labs on filter paper, revived on YPD, stored in YPD+15% glycerol as a mixed population and then analyzed by CHEF and CGH, a process that involved ~50–70 generations of growth on rich medium that did not contain fluconazole. For single colony analysis, clones were derived from a population plated on YPD directly from ~80°C storage. After two days at 30°C single colonies were picked into 5 mL YPD liquid and grown up overnight also at 30°C. Liquid cultures were used to make CHEF agarose plugs (1% low melt agarose), gDNA for CGH or PCR analysis, and were again saved in 15% glycerol at ~80°C. When variation in colony size morphology was observed after plating on YPD, multiple single colonies of each type were analyzed.

Measurement of Relative Fitness. Fitness of isolates from the experimental populations was determined by placing each isolate in direct competition with the progenitor, genetically marked with resistance to nourseothricin (MATI). The progenitor was marked by C-terminally tagging ENO1 with GFP using a MATI selectable marker. The tagging construct was amplified by PCR with primers (Table S1) oLC597 and oLC596 from plasmid pMG2021 [20] and transformed into C. albicans following standard protocols. Transformants were tested for proper integration of the marker by PCR amplification with primers oLC598 and oLC600 as well as with primers oLC599 and oLC601. There was no significant difference in fitness between the marked and unmarked progenitor. Competition experiments were conducted in triplicate both in the presence and in the absence of fluconazole, essentially as described [33]. All competitions were conducted in the same medium as used for the evolution experiment [6], RPMI 1640, at 30°C. For the competitions that were conducted in the presence of drug, the concentration of fluconazole used was twice the most recently measured MIC of the experimental population. The competing populations were first conditioned by growing each competitor from the frozen archive separately overnight in RPMI 1640 medium. Cell counts of the overnight cultures, performed with a hemocytometer, were used to prepare a competition mix containing approximately equal concentrations of the two competitors. One hundred microliters of the competition mix was used to inoculate 9.9 ml of fresh medium (with or without fluconazole), and the competitors were allowed to grow together for 24 hours. Initial and final densities of each culture were determined by colony counts from dilution plates on yeast extract peptone dextrose (YPD) medium. The initial and final densities of each competitor were determined by replica plating the dilution plates onto YPD+NAT; under these conditions, only the genetically marked progenitor is able to grow. Fitness was estimated as the difference in number of doublings of the two competitors (evolved population minus the genetically marked progenitor), standardized by the total number of doublings in the competition assay, as described [33].

Comparative Genome Hybridization

CGH analysis was performed as described previously using arrays produced in house [25]. The same reference control strain, SC5314, was used for all arrays in this paper. Multiple control hybridizations of SC5314 versus itself were performed and a representative example is provided in Figure S2A. Genomic DNA was isolated from cells grown in YPD and was RNaseA treated. 3 μg of DNA was digested with HaeIII for 3–4 hours, purified, and then labeled with Cy3-dUTP (strain of interest) or Cy5-dUTP (SC5314) (Pharmacia/Amersham) using the BioPrime Array CGH labeling Module (Invitrogen). Labeled DNA was purified on a Microcon 30 filter (Millipore), mixed in a 1:1 ratio, and applied to the array for a 16-hour hybridization. Fluorescence intensity ratios (mean log2 values) were obtained and analyzed using GenePixPro 5.1 and GeneTraffic 3.1. A Matlab program was used to plot all log2 data as a function of chromosomal location [25]. The CGH array data are listed in GEO, the Gene Expression Omnibus, as series “CGH analysis of Candida albicans strains after in vitro evolution in the presence or absence of fluconazole” with accession number GSE16423.

CHEF and Sfi digestion

Preparation of cells for CHEF analysis was performed as described previously [25]. Briefly, cells are grown up overnight in
liquid YPD and gently collected by centrifuge and washed several times with 50 mM EDTA. Cells are suspended in 1% low melt agarose and then treated with BME and with Proteinase K solutions. Whole chromosome separation was performed on a BioRad CHEF-DR III with the following program: 60– to 120-s switch, 4.5 V cm−1, 120 angle, for 36 hours, followed by a 120– to 300-s switch, 6.0 V cm−1, 120 angle, for 12 hours. 30 μl digestion of CHEF gel plugs was performed as described previously [11] and separation of these large chromosome fragments was done with the following program: 7– to 100-s switch, 4.5 V cm−1, 120 angle, for 21 hours, followed by 90– to 400-s switch, 3.5 V cm−1, 120 angle, for 21 hours. CHEF gels were stained with Ethidium bromide and transferred to Magnacharge membranes for Southern blot analysis.

CHEF–Southern blot analysis

All Southern blots were performed with DIG labeled probes (Roche) as described previously [23]). Probes were constructed by PCR using DIG-11-dUTP nucleotides (according to the manufacturer’s instructions) and primers that are listed in Table S1.

CGH analysis of an isolated CHEF band

Isolation, labeling and hybridization of the ~1.5 Mb SNC was performed based on the PFGE-array protocol developed by Maitreya Dunham (http://dunham.gs.washington.edu/protocols.shtml). A whole-chromosome CHEF gel was run as described above with 5 lanes of strain YJB10971. The gel was stained with EtBr and the band representing the novel ~1.5 Mb SNC was excised from all 5 lanes. The gel pieces were incubated twice for 1 hour in 4 volumes of water and then incubated in 1× HaeIII buffer (Roche) for 1 hour. Fresh 1× HaeIII buffer and 5 μl HaeIII enzyme (10 units/μl, Roche) were added and incubated overnight at 37°C. DNA was eluted from the gel slice and precipitated with salt and isopropanol. DNA was quantitated using a Nanodrop spectrophotometer and 700 ng of DNA was labeled with Cy3 (as described above), mixed with 700 ng of Cy5-labeled gDNA from SC5314 (as described above), and hybridized to a whole genome microarray.

Fluconazole E-test

Cells were grown to mid-log phase, washed in 0.85% NaCl, and diluted to an OD600 of 0.01. 200–250 μl of cells were plated on Castonse-agar plates using glass beads and allowed to dry for 15–30 minutes before applying a fluconazole E-test strip (0.016–126 μg/ml, AB Biodisk). Plates were incubated at 30°C for 48 hours and the MIC was determined as the first growth-inhibition ellipse.

Exponential growth rate modeling and freeze-thaw analysis

Doubling times were determined by growing populations as well progeny of colonies that contained or did not contain i(5L) in RPMI or RPMI with fluconazole at 0.5 μg/ml, 35°C or in YPD medium at 30°C and at 35°C. D9-3.3-D strains (carrying i(5L)) have doubling times of ~138 min (+/−10 min) in 0.5 μg/ml fluconazole, and thus could have divided up to 10.4 times in 24 hours. In contrast, the progenitor strain (without i(5L)) had a doubling time of ~126 min (+/−9 min) in 0.5 μg/ml fluconazole; these cells consistently divided twice and then stopped dividing. Similar results were seen when T118 progenitor cells were grown in fluconazole and analyzed by time-lapse microscopy. Modeling of the exponential growth phase in the presence of drug based on these data indicates that if i(5L) cells divided once every ~2.3 hours (138 min), and the non-i(5L) cells divided only twice in the 24 hour period, and if ~1×10^5 cells/ml were used to start the 24 hour culture (a number that was determined by measuring cell number after preparing starter cultures using conditions identical to those used in the original experiment [6]). If we assume one i(5L) cell appeared within first 1–2 hours after culture dilution into RPMI + fluconazole, that cell could have reached ~0.3% of the culture after 24 hours. Because cells were stored in medium containing fluconazole, cells would have remained under selective pressure when resuscitated if residual drug remained active in the stored cultures and was not diluted upon streaking of cells from the frozen stock vial. In this case, cells containing i(5L) could have reached 15–20% of the culture over the next 16 hours of growth, based on the assumptions about growth rates as detailed above.

We performed several assays to determine if D9-3.3-D cells (with i(5L)) have any growth advantage on YPD media. We mixed progenitor and D9-3.3-D cells in a 1:1 mixture and a 1:99 (i(5L) to progenitor) mixtures. The mixtures were plated on YPD before freezing, after one freeze-thaw, and after three freeze-thaw cycles. In none of these experiments did D9-3.3-D cells have a growth advantage relative to the progenitor.

Supporting Information

**Figure S1** Single colony karyotype analysis of parental strain T118 and D9 populations. CHEF gel analysis followed by hybridization of the Southern blot with a probe to CEN5 revealed that all single colonies derived from T118 had the same karyotype including two, separable Chr5 homologs. CHEF/Southern analysis of single colonies from generations D9-3.3, D9-140, D9-200, and D9-260 identified i(5L) (arrowhead) in some or all of the clones analyzed. In D9-260, an additional ~1.5 Mb SNC hybridized to CEN5 (arrow).

Found at: doi:10.1371/journal.pgen.1000705.s001 (7.16 MB TIF)

**Figure S2** Single colony karyotype analysis of D11 generations D11-3.3, D11-50, D11-140, D11-200, D11-260, and D11-330. CHEF gel analysis followed by Southern blot with a probe to CEN5 shows that the percentage of clones within each population that carried i(5L) (arrowhead) varied from 50% to 100% during the evolution experiment (summarized in Table 1).

Found at: doi:10.1371/journal.pgen.1000705.s002 (10.04 MB TIF)

**Figure S3** Single colony karyotype analysis of D12 generations D12-3.3, D12-50, D12-230, and D11-260. CHEF gel analysis followed by Southern blot with a probe to CEN5 shows that the percentage of clones within each population that carried the att-i(5L) (arrowhead) varied from 20% to 100% during the evolution experiment (summarized in Table 1).

Found at: doi:10.1371/journal.pgen.1000705.s003 (7.80 MB TIF)

**Figure S4** Comparative genome hybridization of (A) the ancestral strain T118, (B) the MAT7-marked clone of T118 used for all fitness competitions, (C) population N1-330, (D) population N2-330, (E) population N3-330, (F) population N4-330, (G) population N5-330, (H) population N6-330. No aneuploidy was detected in these populations.

Found at: doi:10.1371/journal.pgen.1000705.s004 (4.78 MB TIF)

**Figure S5** Comparative genome hybridization of the reference control SC5314 versus SC5314 (A) and of single colonies from populations; (B) N1-330, (C) N2-330, (D) N3-330, (E) N4-330, and (F) N5-330. No aneuploidy was detected in these clones.

Found at: doi:10.1371/journal.pgen.1000705.s005 (3.66 MB TIF)

**Figure S6** Comparative genome hybridization of D9. (A) D9-165 contains i(5L) and Chr7 trisomy, (B) in clone D9-260-b the i(5L) with
additional Chr5L copies and Chr6 and Chr7 trisomies, while (C) D9-330 has i(5L), trisomy of Chr4, Chr6, and Chr7, Chr3 monosomy, and a small increase in copy number on the right arm of Chr5 (at the same breakpoint found on the i(5L)-3R chromosome, asterisk).

**References**

1. Cannon RD, Lamping E, Holmes AR, Niimi K, Tanabe K, et al. (2007) *Candida albicans* drug resistance another way to cope with stress. Microbiology 153: 3211–3217.

2. Cowen LE (2008) The evolution of fungal drug resistance: modulating the trajectory from genotype to phenotype. Nat Rev Microbiol 6: 167–180.

3. Marc KA, Seidel K, White TC, Bowden RA (2008) Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis 181: 309–316.

4. White TC, Marr KA, Bowden RA (1998) Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev 11: 392–402.

5. Hamza OJ, Matee MI, Moshi MJ, Simon EN, Mugusi F, et al. (2008) Species determination and in vitro antifungal susceptibility of oral yeast isolates from Tanzanian HIV-infected patients with primary and recurrent oropharyngeal candidiasis. BMC Microbiol 8: 135.

6. Cowen LE, Sanghera D, Calabrese D, Sirjung J, Anderson JB, et al. (2000) Evolution of drug resistance in experimental populations of *Candida albicans*. J Bacteriol 182: 1515–1522.

7. Duesberg P, Stindl R, Hehlmann R (2001) Origin of multidrug resistance in cells formed by aneuploidy. Proc Natl Acad Sci U S A 98: 11283–11288.

8. Dunn ML, Badrane H, Ferea T, Adams J, Brown PO, et al. (2002) Comparative genomic characterization of *Candida albicans* strain SC5314. J Bacteriol 184: 100–108.

9. Dunham MJ, Battarne H, Ferea T, Adams J, Brown PO, et al. (2002) Characteristic genome rearrangements in experimental evolution of *Saccharomyces cerevisiae*. Proc Natl Acad Sci U S A 99: 13794–13799.

10. Dunham MJ, Battarne H, Ferea T, Adams J, Brown PO, et al. (2002) Characteristic genome rearrangements in experimental evolution of *Saccharomyces cerevisiae*. Proc Natl Acad Sci U S A 99: 13794–13799.

11. Dunham MJ, Battarne H, Ferea T, Adams J, Brown PO, et al. (2002) Characteristic genome rearrangements in experimental evolution of *Saccharomyces cerevisiae*. Proc Natl Acad Sci U S A 99: 13794–13799.

12. Dunham MJ, Battarne H, Ferea T, Adams J, Brown PO, et al. (2002) Characteristic genome rearrangements in experimental evolution of *Saccharomyces cerevisiae*. Proc Natl Acad Sci U S A 99: 13794–13799.

13. Dunham MJ, Battarne H, Ferea T, Adams J, Brown PO, et al. (2002) Characteristic genome rearrangements in experimental evolution of *Saccharomyces cerevisiae*. Proc Natl Acad Sci U S A 99: 13794–13799.

14. Dunham MJ, Battarne H, Ferea T, Adams J, Brown PO, et al. (2002) Characteristic genome rearrangements in experimental evolution of *Saccharomyces cerevisiae*. Proc Natl Acad Sci U S A 99: 13794–13799.

15. Dunham MJ, Battarne H, Ferea T, Adams J, Brown PO, et al. (2002) Characteristic genome rearrangements in experimental evolution of *Saccharomyces cerevisiae*. Proc Natl Acad Sci U S A 99: 13794–13799.

16. Dunham MJ, Battarne H, Ferea T, Adams J, Brown PO, et al. (2002) Characteristic genome rearrangements in experimental evolution of *Saccharomyces cerevisiae*. Proc Natl Acad Sci U S A 99: 13794–13799.

17. Dunham MJ, Battarne H, Ferea T, Adams J, Brown PO, et al. (2002) Characteristic genome rearrangements in experimental evolution of *Saccharomyces cerevisiae*. Proc Natl Acad Sci U S A 99: 13794–13799.

18. Dunham MJ, Battarne H, Ferea T, Adams J, Brown PO, et al. (2002) Characteristic genome rearrangements in experimental evolution of *Saccharomyces cerevisiae*. Proc Natl Acad Sci U S A 99: 13794–13799.

19. Dunham MJ, Battarne H, Ferea T, Adams J, Brown PO, et al. (2002) Characteristic genome rearrangements in experimental evolution of *Saccharomyces cerevisiae*. Proc Natl Acad Sci U S A 99: 13794–13799.

20. Dunham MJ, Battarne H, Ferea T, Adams J, Brown PO, et al. (2002) Characteristic genome rearrangements in experimental evolution of *Saccharomyces cerevisiae*. Proc Natl Acad Sci U S A 99: 13794–13799.

21. Dunham MJ, Battarne H, Ferea T, Adams J, Brown PO, et al. (2002) Characteristic genome rearrangements in experimental evolution of *Saccharomyces cerevisiae*. Proc Natl Acad Sci U S A 99: 13794–13799.

22. Dunham MJ, Battarne H, Ferea T, Adams J, Brown PO, et al. (2002) Characteristic genome rearrangements in experimental evolution of *Saccharomyces cerevisiae*. Proc Natl Acad Sci U S A 99: 13794–13799.

23. Dunham MJ, Battarne H, Ferea T, Adams J, Brown PO, et al. (2002) Characteristic genome rearrangements in experimental evolution of *Saccharomyces cerevisiae*. Proc Natl Acad Sci U S A 99: 13794–13799.

24. Dunham MJ, Battarne H, Ferea T, Adams J, Brown PO, et al. (2002) Characteristic genome rearrangements in experimental evolution of *Saccharomyces cerevisiae*. Proc Natl Acad Sci U S A 99: 13794–13799.

25. Dunham MJ, Battarne H, Ferea T, Adams J, Brown PO, et al. (2002) Characteristic genome rearrangements in experimental evolution of *Saccharomyces cerevisiae*. Proc Natl Acad Sci U S A 99: 13794–13799.

26. Dunham MJ, Battarne H, Ferea T, Adams J, Brown PO, et al. (2002) Characteristic genome rearrangements in experimental evolution of *Saccharomyces cerevisiae*. Proc Natl Acad Sci U S A 99: 13794–13799.

27. Dunham MJ, Battarne H, Ferea T, Adams J, Brown PO, et al. (2002) Characteristic genome rearrangements in experimental evolution of *Saccharomyces cerevisiae*. Proc Natl Acad Sci U S A 99: 13794–13799.

28. Dunham MJ, Battarne H, Ferea T, Adams J, Brown PO, et al. (2002) Characteristic genome rearrangements in experimental evolution of *Saccharomyces cerevisiae*. Proc Natl Acad Sci U S A 99: 13794–13799.

29. Dunham MJ, Battarne H, Ferea T, Adams J, Brown PO, et al. (2002) Characteristic genome rearrangements in experimental evolution of *Saccharomyces cerevisiae*. Proc Natl Acad Sci U S A 99: 13794–13799.

30. Dunham MJ, Battarne H, Ferea T, Adams J, Brown PO, et al. (2002) Characteristic genome rearrangements in experimental evolution of *Saccharomyces cerevisiae*. Proc Natl Acad Sci U S A 99: 13794–13799.

31. Dunham MJ, Battarne H, Ferea T, Adams J, Brown PO, et al. (2002) Characteristic genome rearrangements in experimental evolution of *Saccharomyces cerevisiae*. Proc Natl Acad Sci U S A 99: 13794–13799.

32. Dunham MJ, Battarne H, Ferea T, Adams J, Brown PO, et al. (2002) Characteristic genome rearrangements in experimental evolution of *Saccharomyces cerevisiae*. Proc Natl Acad Sci U S A 99: 13794–13799.

33. Dunham MJ, Battarne H, Ferea T, Adams J, Brown PO, et al. (2002) Characteristic genome rearrangements in experimental evolution of *Saccharomyces cerevisiae*. Proc Natl Acad Sci U S A 99: 13794–13799.

34. Dunham MJ, Battarne H, Ferea T, Adams J, Brown PO, et al. (2002) Characteristic genome rearrangements in experimental evolution of *Saccharomyces cerevisiae*. Proc Natl Acad Sci U S A 99: 13794–13799.

35. Dunham MJ, Battarne H, Ferea T, Adams J, Brown PO, et al. (2002) Characteristic genome rearrangements in experimental evolution of *Saccharomyces cerevisiae*. Proc Natl Acad Sci U S A 99: 13794–13799.

36. Dunham MJ, Battarne H, Ferea T, Adams J, Brown PO, et al. (2002) Characteristic genome rearrangements in experimental evolution of *Saccharomyces cerevisiae*. Proc Natl Acad Sci U S A 99: 13794–13799.

37. Dunham MJ, Battarne H, Ferea T, Adams J, Brown PO, et al. (2002) Characteristic genome rearrangements in experimental evolution of *Saccharomyces cerevisiae*. Proc Natl Acad Sci U S A 99: 13794–13799.
24. Bouchonville K, Forche A, Tang KES, Selmecki AM, Berman J (2009) Aneuploid chromosomes are highly unstable during DNA transformation of Candida albicans. Eukaryotic Cell.

25. Selmecki A, Bergmann N, Berman J (2005) Comparative genome hybridization reveals widespread aneuploidy in Candida albicans laboratory strains. Mol Microbiol 55: 1553–1563.

26. Coste AT, Turner V, Ischer F, Morschhauser J, Forche A, et al. (2006) A mutation in Tac1p, a transcription factor regulating CDR1 and CDR2, is coupled with loss of heterozygosity at Chromosome 5 to mediate antifungal resistance in Candida albicans. Genetics 172: 2139–2156.

27. White TC (1997) Increased mRNA levels of ERG16, CDR, and MDRI correlate with increases inazole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus. Antimicrob Agents Chemother 41: 1482–1487.

28. Cowen LE, Nantel A, Whiteway MS, Thomas DY, Tessier DC, et al. (2002) Population genomics of drug resistance in Candida albicans. Proc Natl Acad Sci U S A 99: 9284–9290.

29. Gresham D, Desai MM, Tucker CM, Jenq HT, Pai DA, et al. (2008) The repertoire and dynamics of evolutionary adaptations to controlled nutrient-limited environments in yeast. PLoS Genet 4: e1000303. doi:10.1371/journal.pgen.1000303.

30. Lenski RE, Winkworth CL, Riley MA (2003) Rates of DNA sequence evolution in experimental populations of Saccharomyces cerevisiae. Genetics 164: 1913–1923.

31. Brown CJ, Todd KM, Rosenzweig RF (1998) Multiple duplications of yeast hexose transport genes in response to selection in a glucose-limited environment. Mol Biol Evol 15: 931–942.

32. Kao KC, Sherlock G (2008) Molecular characterization of clonal interference during adaptive evolution in sexual populations of Saccharomyces cerevisiae. Nat Genet 40: 1499–1504.

33. Cowen LE, Kohn LM, Anderson JB (2001) Divergence in fitness and evolution of drug resistance in experimental populations of Candida albicans. J Bacteriol 183: 2971–2978.

34. Gonzalez C, Hadany L, Ponder RG, Price M, Hastings PJ, et al. (2008) Mutability and importance of a hypermutable cell subpopulation that produces stress-induced mutants in Escherichia coli. PLoS Genet 4: e1000208. doi:10.1371/journal.pgen.1000208.

35. Duesberg P, Li R (2003) Multistep carcinogenesis: a chain reaction of aneuploidizations. Cell Cycle 2: 202–210.

36. Cruz MC, Goldstein AL, Blankenship JR, Del Poeta M, Davis D, et al. (2002) Calcineurin is essential for survival during membrane stress in Candida albicans. EMBO J 21: 546–559.

37. Sanglard D, Iserh F, Marchetti O, Entenza J, Bille J (2003) Calcineurin A of Candida albicans: involvement in antifungal tolerance, cell morphogenesis and virulence. Mol Microbiol 48: 959–976.

38. Cowen LE, Landquist S (2003) Hap90 potentiates the rapid evolution of new traits: drug resistance in diverse fungi. Science 309: 2185–2189.

39. Yuvasubhoj D, Unal F, Yilmaz S, Aksoy H, Celik M (2008) Genotoxicity testing of fluconazole in vivo and in vitro. Mutat Res 649: 155–160.

40. Anderson JB, Sirjusingh C, Ricker N (2004) Haploidy, diploidy and evolution of antifungal drug resistance in Saccharomyces cerevisiae. Genetics 168: 1913–1923.

41. Bennett RJ, Johnson AD (2003) Completion of a parasexual cycle in Candida albicans by induced chromosome loss in tetraploid strains. Embo J 22: 2505–2515.

42. Hughes TR, Roberts CJ, Dai H, Jones AR, Meyer MR, et al. (2000) Widespread aneuploidy revealed by DNA microarray expression profiling. Nat Genet 25: 333–337.

43. Forche A, Magee P, Selmecki A, Berman J, May G (2009) Evolution in Candida albicans Populations During Single Passage Through a Mouse Host. Genetics.

44. Rustad TR, Stevens DA, Pfaffer MA, White TC (2002) Homozygosity at the Candida albicans MTL locus associated with azole resistance. Microbiology 148: 1061–1072.

45. Sanglard D, Kuchler K, Ischer F, Pagani JL, Monod M, et al. (1995) Mechanisms of resistance toazole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters. Antimicrob Agents Chemother 39: 2378–2386.

46. Liu TT, Lee RE, Barker KS, Lee RE, Wei L, et al. (2005) Genome-wide expression profiling of the response toazole, polyene, echinocandin, and pyrimidineantifungal agents in Candida albicans. Antimicrob Agents Chemother 49: 2226–2236.

47. Torres EM, Sokolky T, Tucker CM, Chau LY, Boselli M, et al. (2007) Effects of aneuploidy oncellularphysiology and celldivision in haploid yeast. Science 317: 916–924.

48. Williams BR, Prlhbnu VR, Hunter KE, Glazier CM, Whittaker CA, et al. (2008) Aneuploidy affects proliferation and spontaneous immortalization in mamma-lined cells. Science 322: 703–709.

49. Torres EM, Williams BR, Amou A (2008) Aneuploidy: cells losing their balance. Genetics 179: 737–746.